Gustafson D - Search Results

1

ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.

Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. Frederick B, et al. Among authors: gustafson d. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):33-7. doi: 10.1016/j.ijrobp.2005.05.050. Int J Radiat Oncol Biol Phys. 2006. PMID: 16377413

2

Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.

Zirrolli JA, Bradshaw EL, Long ME, Gustafson DL. Zirrolli JA, et al. J Pharm Biomed Anal. 2005 Sep 15;39(3-4):705-11. doi: 10.1016/j.jpba.2005.04.024. J Pharm Biomed Anal. 2005. PMID: 15935603

3

Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing.

Gustafson DL, Bradshaw-Pierce EL, Merz AL, Zirrolli JA. Gustafson DL, et al. J Pharmacol Exp Ther. 2006 Aug;318(2):872-80. doi: 10.1124/jpet.106.102376. Epub 2006 Apr 27. J Pharmacol Exp Ther. 2006. PMID: 16644900

4

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr. Helfrich BA, et al. Among authors: gustafson d. Clin Cancer Res. 2006 Dec 1;12(23):7117-25. doi: 10.1158/1078-0432.CCR-06-0760. Clin Cancer Res. 2006. PMID: 17145836

5

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.

Gustafson DL, Frederick B, Merz AL, Raben D. Gustafson DL, et al. Cancer Chemother Pharmacol. 2008 Feb;61(2):179-88. doi: 10.1007/s00280-007-0460-5. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2008. PMID: 17393165

6

Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG. Troiani T, et al. Clin Cancer Res. 2007 Nov 1;13(21):6450-8. doi: 10.1158/1078-0432.CCR-07-1094. Clin Cancer Res. 2007. PMID: 17975157

7

Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.

Bradshaw-Pierce EL, Steinhauer CA, Raben D, Gustafson DL. Bradshaw-Pierce EL, et al. Among authors: gustafson dl. Mol Cancer Ther. 2008 Sep;7(9):3006-17. doi: 10.1158/1535-7163.MCT-08-0370. Mol Cancer Ther. 2008. PMID: 18790781 Free PMC article.

8

Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.

Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI. Diamond JR, et al. Clin Cancer Res. 2011 Feb 15;17(4):849-60. doi: 10.1158/1078-0432.CCR-10-2144. Epub 2010 Dec 3. Clin Cancer Res. 2011. PMID: 21131552 Free PMC article. Clinical Trial.

9

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.

Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Thienelt CD, et al. Among authors: gustafson dl. J Clin Oncol. 2005 Dec 1;23(34):8786-93. doi: 10.1200/JCO.2005.03.1997. Epub 2005 Oct 24. J Clin Oncol. 2005. PMID: 16246975 Clinical Trial.

10

A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.

Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. Basche M, et al. Clin Cancer Res. 2006 Sep 15;12(18):5471-80. doi: 10.1158/1078-0432.CCR-05-2423. Clin Cancer Res. 2006. PMID: 17000682 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

925 results

Search Page

Filters